“…As one of the first identified cancer‐associated lncRNAs, MALAT1 was reported to be overexpressed in gastric cancer (Chen, Liu, Wang et al, 2017), breast cancer (Arun et al, ), prostate cancer (Ren et al, ), cervical cancer (Sun, Qin et al, ), acute myeloid leukemia (Chen, Nagel et al, 2018), medullary thyroid cancer (Chu, Hardin, Schneider, Chen, & Lloyd, ), choriocarcinoma (Shi, Wang, & Yin, ), gallbladder cancer (Sun et al, ), pancreatic cancer (Xie et al, 2017), multiple myeloma (Liu, Wang et al, ), ovarian cancer (Wu et al, 2017), T and natural killer cell lymphoma (Kim, Kim, Yang, Kim, & Yoon, ), acute monocytic leukemia (Huang, Liu et al, ), endometrial stromal sarcoma (Yamada et al, ), myeloma (Cho et al, ), clear cell renal cell carcinoma (Zhang, Yang, Chen, Che, & Zheng, ), esophageal squamous cell carcinoma (Hu et al, ), glioma (Ma, Wang, Li et al, ), osteosarcoma (Cai et al, ), neuroblastoma (Tee et al, ), tongue squamous cell carcinomas (Fang et al, ), hilar cholangiocarcinoma (Tan, Huang, & Li, ), mantle cell lymphoma (Wang, Zhu et al, ), and other tumor tissues. It has been reported that MALAT1 is involved in the regulation of tumor proliferation, apoptosis, invasion, metastasis, and angiogenesis.…”